ResearcherTianjin Medical University General HospitalActive in the last 2 years

Guannan Sheng

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5091890194. Sources: OpenAlex.

Their work

Papers: 3 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 18

Papers, trials and grants by year

2024: 2 papers · 2025: 1 paper

Papers 3

CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. Co-author DOI 10.20892/j.issn.2095-3941.2025.0058 ↗
Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma. First author DOI 10.20892/j.issn.2095-3941.2023.0363 ↗
PLPP2 as a metabolic and immune marker for predicting survival and enhancing response to anti-PD1 therapy in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-3952664/v1 ↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Bo Ni · 2 shared papers, 2024–2025 · strength 0.41
- Paper PLPP2 as a metabolic and immune marker for predicting survival and enhancing response to anti-PD1 therapy in pancreatic… DOI 10.21203/rs.3.rs-3952664/v1 ↗
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058 ↗
Yongjie Xie · 2 shared papers, 2024–2025 · strength 0.41
- Paper PLPP2 as a metabolic and immune marker for predicting survival and enhancing response to anti-PD1 therapy in pancreatic… DOI 10.21203/rs.3.rs-3952664/v1 ↗
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058 ↗
Song Gao · 2 shared papers, 2024–2025 · strength 0.39
- Paper Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ducta… DOI 10.20892/j.issn.2095-3941.2023.0363 ↗
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058 ↗
Tao Yang · 1 shared paper, 2024 · strength 0.23
- Paper PLPP2 as a metabolic and immune marker for predicting survival and enhancing response to anti-PD1 therapy in pancreatic… DOI 10.21203/rs.3.rs-3952664/v1 ↗
Quan Man · 1 shared paper, 2024 · strength 0.21
- Paper Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ducta… DOI 10.20892/j.issn.2095-3941.2023.0363 ↗
Yuexiang Liang · 1 shared paper, 2024 · strength 0.21
- Paper Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ducta… DOI 10.20892/j.issn.2095-3941.2023.0363 ↗
Yiping Zou · 1 shared paper, 2024 · strength 0.21
- Paper Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ducta… DOI 10.20892/j.issn.2095-3941.2023.0363 ↗
Shaofei Chang · 1 shared paper, 2024 · strength 0.21
- Paper Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ducta… DOI 10.20892/j.issn.2095-3941.2023.0363 ↗
Jihui Hao · 1 shared paper, 2024 · strength 0.21
- Paper Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ducta… DOI 10.20892/j.issn.2095-3941.2023.0363 ↗
Shengyu Yang · 1 shared paper, 2025 · strength 0.18
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058 ↗
Chunhua She · 1 shared paper, 2025 · strength 0.18
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058 ↗
Liangliang Wu · 1 shared paper, 2025 · strength 0.18
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058 ↗
Chongbiao Huang · 1 shared paper, 2025 · strength 0.18
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058 ↗
Chao Xu · 1 shared paper, 2025 · strength 0.18
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058 ↗
Xiuchao Wang · 1 shared paper, 2025 · strength 0.18
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058 ↗
Kaiyuan Wang · 1 shared paper, 2025 · strength 0.18
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058 ↗
Tiansuo Zhao · 1 shared paper, 2025 · strength 0.18
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058 ↗
Tianxing Zhou · 1 shared paper, 2025 · strength 0.18
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.